Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Annette Marcantonio
Efficacy and Safety of AR101 in Peanut Allergy: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Related publications
Prevalence of Comorbidities With Peanut Allergy: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Impact of Peanut Allergy on Quality of Life: Baseline Results From PALISADE, a Phase 3, Double-Blind, Placebo-Controlled Trial for AR101 Oral Immunotherapy
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
Pediatrics
Child Health
Pediatrics
Perinatology
Estimating the Probability of Tolerating Each Challenge Dose of Peanut Protein at Exit Double-Blind, Placebo-Controlled Food Challenge: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE) of AR101
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Accidental Exposures to Peanut and Other Food Allergens: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Efficacy and Safety of Baclofen for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial
Alcoholism: Clinical and Experimental Research
Medicine
Psychiatry
Mental Health
Toxicology
Longer-Term Safety and Efficacy Measures of AR101 Oral Immunotherapy for Peanut Allergy: Results From a Phase 3 Follow-On Study
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Efficacy of Pregabalin in Post-Traumatic Peripheral Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
Journal of Neurology
Neurology
Long-Term Efficacy and Safety of Brodalumab in the Treatment of Psoriasis: 120-Week Results From the Randomized, Double-Blind, Placebo- And Active Comparator–controlled Phase 3 AMAGINE-2 Trial
Journal of the American Academy of Dermatology
Dermatology
